Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Sreyashi DasMohan Kumar DeyRam DevireddyManas Ranjan GartiaPublished in: Sensors (Basel, Switzerland) (2023)
Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis, prognosis, treatment response, and personalized medicine. They serve as objective indicators, enabling early detection and intervention, leading to improved patient outcomes and reduced costs. Biomarkers also guide treatment decisions by predicting disease outcomes and facilitating individualized treatment plans. They play a role in monitoring disease progression, adjusting treatments, and detecting early signs of recurrence. Furthermore, biomarkers enhance drug development and clinical trials by identifying suitable patients and accelerating the approval process. In this review paper, we described a variety of biomarkers applicable for cancer detection and diagnosis, such as imaging-based diagnosis (CT, SPECT, MRI, and PET), blood-based biomarkers (proteins, genes, mRNA, and peptides), cell imaging-based diagnosis (needle biopsy and CTC), tissue imaging-based diagnosis (IHC), and genetic-based biomarkers (RNAseq, scRNAseq, and spatial transcriptomics).
Keyphrases
- healthcare
- high resolution
- clinical trial
- randomized controlled trial
- computed tomography
- magnetic resonance imaging
- type diabetes
- ultrasound guided
- papillary thyroid
- stem cells
- newly diagnosed
- magnetic resonance
- open label
- mass spectrometry
- photodynamic therapy
- prognostic factors
- positron emission tomography
- skeletal muscle
- copy number
- peritoneal dialysis
- patient reported outcomes
- cell therapy
- social media
- health insurance
- combination therapy
- glycemic control
- pet imaging
- real time pcr
- drug administration